Argenx Advances CIDP Treatment with New Clinical Study Update

Argenx ((ARGX)) announced an update on their ongoing clinical study.

Study Overview: Argenx is conducting a Phase 4 clinical study titled A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC. The study aims to evaluate how adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) transition from intravenous immunoglobulin (IVIg) therapy to efgartigimod PH20 SC, highlighting its potential significance in improving patient care.

Intervention/Treatment: The intervention being tested is efgartigimod PH20 SC, a biological treatment administered via subcutaneous injection. It is designed to replace IVIg therapy, potentially offering a more convenient treatment option for CIDP patients.

Study Design: This interventional study follows an open-label, single-group design, meaning all participants receive the same treatment without a placebo group. The primary purpose is treatment-focused, with no masking involved, allowing researchers to directly observe the effects of efgartigimod PH20 SC on participants.

Study Timeline: The study began on December 10, 2024, with a primary completion date yet to be announced. The most recent update was submitted on July 15, 2025. These dates are crucial for tracking the study’s progress and anticipating results.

Market Implications: This study update could positively impact Argenx’s stock performance by showcasing their commitment to advancing CIDP treatment. Successful results might enhance investor confidence and position Argenx favorably against competitors in the neurology treatment market.

The study is currently ongoing, with further details available on the ClinicalTrials portal.